News
-
09.02.2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C - -
04.02.2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
Home
| Debio 8609 |
|
Debio 8609, Sanvar® is synthetic octapeptide analogue of the naturally-occurring somatostatin hormone for the treatment of esophageal variceal bleeding. Sanvar® is used prior to endoscopic intervention to control haemorrhage and prevent re-bleeding during the critical five days following the onset of bleeding. In November 2008, Debiopharm submitted an NDA (new drug application) with the U.S. Food and Drug Administration for Sanvar®.
Press Releases04-Nov-2008 21-Feb-2008 23-Oct-2006 05-Sep-2006 24-Jul-2006 -> All Press Releases
Publications05-Nov-2003 |



